
---
title: '银河证券：国内医药创新的大时代已经来临 新药研发的收获期正在到来'
categories: 
 - 金融
 - 证券时报网
 - 快讯
headimg: 'https://picsum.photos/400/300?random=984'
author: 证券时报网
comments: false
date: Thu, 06 Jan 2022 14:46:00 GMT
thumbnail: 'https://picsum.photos/400/300?random=984'
---

<div>   
<p>证券时报网讯，银河证券指出，创新是医药行业的永恒主题。全球范围来看，医药行业的投资机会紧密围绕创新展开。重磅新药可带来丰厚的经济效益，因此创新药研发对全球医药巨头意义非凡。看好具备持续创新能力的创新药械公司。2020年我国有多款创新药获批或报产。我们认为国内医药创新的大时代已经来临，新药研发的收获期正在到来。看好创新药龙头<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SS600276" code="600276">恒瑞医药</a>、创新器械龙头<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SZ300760" code="300760">迈瑞医疗</a>，同时关注<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SZ300558" code="300558">贝达药业</a>等。看好服务于创新药的CRO、CDMO公司，看好创新服务产业链公司凭借“卖水者”逻辑保持高景气。看好<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SZ002821" code="002821">凯莱英</a>，同时关注<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SS603259" code="603259">药明康德</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SS603127" code="603127">昭衍新药</a>和<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="http://info.stcn.com/dc/stock/?stockcode=SZ300347" code="300347">泰格医药</a>等。</p>

                  
</div>
            